Tramadol, including Ultram, has been used off label for the treatment of the following conditions:
Doses range from 50–400 mg daily, maximum dose of 400 mg a day according to the German package insert for both Grünethal’s product Tramadol 100 mg extended-release tablets and the Tramundal (Mundipharma Ges. m.b.H) 100 mg/ml dropper bottles and 100 and 200 ml dosage pump bottles), with up to 600 mg daily when given IV/IM. The formulation containing APAP contains 37.5 mg of tramadol and 325 mg of paracetamol, intended for oral administration with a common dosing recommendation of one or two tablets every four to six hours.
Ultram has a characteristic taste which is mildly bitter but much less so than morphine and codeine. Oral and sublingual drops and liquid preparations of tramadol come with and without added flavouring. Its relative effectivness via transmucousal routes (sublingual, buccal, rectal) is similar to that of codeine and like codeine it is also metabolised in the liver to stronger metabolites.
Tramadol has been experimentally used in the form of an ingredient in multi-agent topical gels, creams, and solutions for nerve pain, rectal foam, concentrated retention enaema, and a skin plaster (transdermal patch) quite similar to those used with lidocaine.
Tramadol, including Ultram, responds very well to opioid potentiators used to reduce the amount of medication needed to stop a given level of pain. The most effective appears to be promethazine, which also increases the percentage of the drug changed to stronger active metabolites in the liver as it does with the codeine-based opioid analgesics. Orphenadrine, hydroxyzine, diphenhydramine, chlorpheniramine, carisoprodol and benzodiazepines are commonly-used potentiators for tramadol and other drugs in its range of efficacy. Clonidine can reduce side effects and raise the de facto daily dosage ceiling for tramadol but may also competitively reduce the effects on nerve pain in some patients while having no effect or intensifying it in others.
Carbamazepine and some other agents can affect metabolism in such a way that tramadol single and 24-hour doses may have to be increased by as much as 120 per cent to have the same effect. In some patients, fluoxetine use within 15 days prior to starting tramadol can reduce the effectiveness of tramadol by the same Cytochrome p450-related mechanism that causes fluoxetine to wipe out the usefulness of codeine, dihydrocodeine, and similar drugs for a similar period. Combining fluoxetine and tramadol can increase the potential of some tramadol side effects and if done requires very close medical supervision and often can be made less problematic by the addition of a drug with antiserotonergic effects such as cyproheptadine, various phenothiazines, and anticonvulsants if the continuation of fluoxetine is important.
In addition to its use as the primary centrally-acting analgesic, Ultram can also be used with opioids in the place of adjuvants such as duloxetine to help combat neuropathic pain by broadening the spectrum of actions of the primary opioid; this is very useful with morphine, codeine, and its derivatives, somewhat useful with methadone, piritramide, and levorphanol (possibly because tramadol duplicates much more of the spectrum of effects of these drugs) and should be used only very cautiously with pethidine and most of its derivatives due to additive effects which can have toxic CNS and peripheral effects. Ultram can generally be used alongside many other commonly used adjuvants like orphenadrine and related drugs, although those with impacts on serotonin and norepinephrine levels such as amitryptiline, cyclobenzaprine, duloxetine, and MAO inhibitors should be used alongside tramadol with caution and often with reduced doses of both agents.
Tramadol is usually marketed as the hydrochloride salt (tramadol hydrochloride); the tartrate is seen on rare occasions. Cheap Tramadol cod is available in both injectable (intravenous and/or intramuscular) and oral preparations. It is also available in conjunction with paracetamol (acetaminophen). The solutions suitable for injection are used in Patient Controlled Analgesia pumps under some circumstances, either as the sole agent or along with another agent such as morphine.
Tramadol is available in many formulations including:
Tramadol, which is also marketed as Ultram and Ultram ER, is indicated to treat moderate and severe pain and most types of neuralgia, including trigeminal neuralgia. Some studies have indicated that tramadol could be effective in treating the symptoms of depression and anxiety because of its effects and action upon the noradrenergic and serotonergic systems. Ultram appears to play a role in the ability to alleviate the perception of pain on behalf of a patient because of its action upon the noradrenergic and serotonergic systems. However, healthcare professionals have not yet endorsed widespread use of Ultram on a large scale to treat disorders such as depression and anxiety.
Tramadol was developed by the German pharmaceutical company Grünenthal GmbH in the late 1970s and was marketed under the trade name Tramal. Tramadol is the generic name of this drug and has been cross licensed between Grünenthal and other pharmaceutical companies throughout the world and is marketed under several brand names including MEDTRAP (NEOMED), ULTRAM® and ULTRAM® ER.
Tramadol’s has a unique chemical structure that is different from those of opioids. The closest chemical relative of tramadol in clinical use is tapentadol, which is a member of the same chemical class as tramadol and also developed by Grünethal.
Tramadol (pronounced tram-ah-doll) is a central nervous system depressant and analgesic. It is indicated for treating moderate to severe pain. It is a synthetic agent, and it appears to have actions at the µ-opioid receptor as well as the noradrenergic and serotonergic systems.